NasdaqGM:GPCR
NasdaqGM:GPCRPharmaceuticals

Structure Therapeutics (GPCR) Falls Deeper into Losses and Seeks $250M—Is Its Funding Model Sustainable?

Structure Therapeutics Inc. recently reported a second-quarter net loss of US$61.66 million, widening from US$26.03 million a year ago, and for the six-month period, the net loss also increased to US$108.49 million from US$52.07 million in the previous year. Following these results, the company filed for a US$250 million follow-on equity offering and a shelf registration allowing future issuance of various securities including American Depositary Shares, preferred shares, debt securities,...
NYSE:ABT
NYSE:ABTMedical Equipment

Earnings Momentum and Insider Confidence Could Be a Game Changer for Abbott Laboratories (ABT)

Abbott Laboratories recently reported strong financial results, achieving 18% annual earnings per share growth over the past three years and a 5.9% rise in revenue, while insider ownership was valued at US$1.1 billion. This combination of robust performance and significant insider confidence underlines stability in the company's leadership and alignment with shareholder interests. We'll explore how Abbott's large insider ownership and earnings momentum may shape its investment narrative...